gbola amusa md cfa head hc research
sale trade et
viral news genet medicin eu approv zolgensma data
highlight week may may buy chardan top pick partner novarti
unrat announc european condit approv gene therapi gt zolgensma spinal muscular
atrophi sma bi-allel mutat gene either clinic diagnosi sma type
copi gene dose guidanc cover babi young children sma us
ad approv european market strengthen break-up thesi addit zolgensma
royalti stream dividend would accru potenti royalti spin-off vehicl arbutu biopharma buy announc
posit data phase ia/ib trial galnac-rnai therapeut chronic hepat viru hbv hbv
patient receiv singl low dose mg demonstr signific reduct hbsag
follow-up compani plan report multi-dos cohort data make unrat
prefer name drive upsid entir srna mrna space see figur also remov buy
list top pick among srna mrna name april viral news genet medicin last
week vnigm share price move mc april mc
bn friday mc bn us abil scale mrna vaccin manufactur thu
trade support mrna vaccin comp mc bn unrat bn
relat news may may announc posit interim phase data mrna vaccin
report cohort bind antibodi level reach
surpass seen convalesc patient compar discuss march research
elicit neutral antibodi titer level initi particip cohort show safeti
profil consist seen prior infecti diseas vaccin clinic studi inovio unrat
announc public dna vaccin demonstr gener
neutral antibodi cell respons mice guinea pig phase ii/iii efficaci trial plan july/
august pend regulatori approv harvard univers scientist publish scienc studi demonstr lab-
gener dna vaccin protect rhesu macaqu see detail astrazeneca
unrat receiv support barda develop product chimpanze
adenovir vector vaccin co-develop univers oxford institut oxford also
announc began recruit phase ii/iii trial human volunt
look forward may may may lysogen unrat highlight design
gangliosidosi gt trial nation tay sach associ diseas ntsad virtual famili confer
may may american societi clinic oncolog scientif meet held virtual
program includ numer compani genet medicin space adaptimmun therapeut unrat
unrat targovax unrat unrat follow compani report
weekli price move chardan genet medicin vivo gene therapi ex vivo gene therapi
price move sinc februari impact chardan genet medicin vivo gt ex vivo
upcom chardan genet medicin event contact chardan rsvp
pleas refer import disclosur inform regul analyst certif found page report
may chardan annual genet medicin manufactur summit virtual regist particip compani
buy unrat unrat uniqur buy univercel unrat
gene express gene-edit pig organ xenotransplantationfrom sci-fi realiti
gene-edit technolog creat novel approach treat human diseas includ cardiovascular diseas
cancer diabet central nervou system disord see past gene express us one
notabl applic gene edit human xenotransplant transplant implant
infus human organ tissu cell non-human speci
egenesi privat compani focus develop safe effect human transplant organ tissu
cell address global organ shortag co-found genom engin pioneer dr georg church egenesi
develop crispr-edit pig organ compat human lead program preclin pipelin focus
kidney islet cell tissues/organ replac less vital earlier-stag
egenesi program liver heart lung neuron thu mitig patient risk transplant fail
per novemb interview endpoint news egenesi view pig compon platform
see key issu pig organ xenotransplant investig via egenesi research
sinc compani incept elimin porcin endogen retrovirus perv
potenti infect human recipi progress demonstr via disrupt perv pol gene
result reduct perv transmiss human cell risk immunoreject
common issu transplant xenotransplant potenti exist unpreced
unexpect complic deal organ anoth speci compani continu make progress
dimens use gene edit mitig recipi immun respons
compani recent announc acquisit one key manufactur partner icbiotec privat icbiotec
midwest-bas compani expertis clone transgen anim product egenesi plan take
icbiotec facil equip land order establish full control xeno-organ suppli chain therebi
enabl vertic integr egenesi research clone product capabl
applic push boundari gene edit undoubtedli face technic regulatori
hurdl exampl compani technolog incorpor double-digit crispr edit throughout pig genom
theori could significantli increas risk off-target effect compani note howev potenti off-
target effect monitor grow pig prior ever reach patient
net-net believ gene edit xenotransplant technolog worth follow early-stag investor
given proxim egenesi nhp data success technolog could meet great unmet medic
need address global organ shortag per egenesi fda chief requir get clinic
consist preclin result trial non-human primat nhp inde may endpoint news
interview compani guid still track despit pandem creat final condit
genet engin pig ultim harvest organ test non-human primat safeti
efficaci evid egenesi momentum note compani rais mm seri financ round
novemb moreov compani co-found advis dr church whose innov
basi help found mani compani count includ gene therapi gene edit
edita medicin buy gene edit pioneer compani recently-launch privat
util machin learn design synthet aav capsid gene therapi see may commentari dyno
day ipsc i/o edit liver muscl vivo tackl scd may livshit
american societi gene cell therapi asgct virtual meet took place tuesday may
friday may emerg theme relev analyst coverag includ strategi ipsc-deriv
immun cell renew lower-cog cell therapi sourc non-vir liver-direct crispr edit
base edit show interest data technolog platform matur divers edit strategi address
hemoglobin disord associ strength open question nuclease-fre genom edit updat
gene edit approach musculoskelet disord incorpor new technolog
page
ocgn buy pt top-line result phase ogvhd expect end may naka
ocugen announc complet enrol phase trial evalu lead asset treatment
ocular graft versu host diseas ogvhd expect top-line data end year
compani also remain track advanc lead gt product candid phase i/iia clinic
trial expect first-in-human studi target patient either mutat
associ recess retin degener patient rhodopsin mutat associ retin pigmentosa rp
recent preclin data publish march natur gene therapi continu support use
genet modifi therapeut agent treat multipl retin degen diseas data demonstr
abil variou stage retin degener differ diseas mous model rp date
differ disease-caus mutat describ make well valid target
abu buy pt hbv data week much encourag may naka
arbutu biopharma announc interim data phase ia/ib clinic trial evalu lead asset
treatment chronic hepat viru hbv updat includ safeti efficaci data week follow-up
cohort subject chronic hepat infect receiv singl mg dose data show
signific improv hbsag knockdown compar observ day
takeaway safeti profil mg dose clean respons hbeag-neg patient
mean drug trigger miss code viral transcript integr viral dna consist
seen studi would expect hbeag-po patient viral transcript cccdna demonstr
better respons continu knockdown long-term durabl observ mg mg patient
predict anim model suggest similar pattern observ mg effect dose
interv could thu extend everi month longer
leadership call-mustang stabl cell-bas tx asset focu mfg may livshit
may chardan host leadership call unrat manag manni litchman md
presid ceo knut niss phd brian achenbach svp financ control replay
takeaway includ mustang priorit earli invest manufactur underscor central
import cell-bas therapeut consider unmet need limit competit encourag clinic
data make xscid attract opportun despit rariti market may miss mustang car-
program data could chang mustang deep pipelin set catalyst-rich
buy leadership callmarket miss generid vector platform may livshit
may chardan host leadership call logicbio manag fred chereau ceo
matthia jaff cfo kyle chiang phd vice-president product strategi brian luqu ir replay
key takeaway includ market under-appreci logicbio capsid discoveri work use
advanc intern program well drive collabor mma program shown robust preclin
data anim model reflect current diseas manag approach compani posit move
quickli non-cmc-rel issu clinic hold address generid platform provid
durabl benefit diseas earli intervent import
pasg buy leadership calllead indic leadership may amusa
may chardan host leadership call passag manag bruce goldsmith phd ceo
richard morri cfo gari romano md phd replay takeaway includ
 despit on-going pandem passag track catalyst-rich
 passag expand collabor upenn gtp reflect better access best technolog
 recent krabb diseas preclin data present american societi gene cell therapi asgct
annual virtual meet abstract well-receiv excit implic patient
 infantil gangliosidosi krabb diseas condit earli mortal
untreat passag see potenti earlier file clearly-posit phase i/ii data note gt
preced sma xlmtm associ acquisit prior pick avexi audent
 passag cash mm runway focus addit extern partnering/
licens program passag suffici fund enough expertis front
genet medicin news may may
buy announc posit interim phase data mrna vaccin may
unrat announc sustain efficaci phase shine trial spinraza sma may
page
unrat appoint michael price chief offic may
unrat announc price mm public offer common stock may
buy announc price mm public offer common stock may
buy announc price bn public offer common stock may
unrat present data support musk cell treat musk myasthenia gravi may
mayo clinic publish oncolyt activ engin coxsackieviru infecti rna may
univ melbourn publish engin cell express dendrit cell growth factor may
stanford publish hmsc improv wound heal diabet db/db mice may
mit publish new protospac adjac motif recognit adenin dinucleotid may
col wisc publish aav-bas silenc reduc neuropath pain mice may
shanghaitech univers publish review progress aav-bas inner ear disord may
xcur buy appoint dr dougla feltner chief medic offic may
nv unrat announc condit approv zolgensma europ spinal muscular atrophi may
nyu publish lentivir vector-bas dendrit cell vaccin strategi cancer may
institut pasteur publish preclin data lentivir vector-bas vaccin zika viru may
psl univ publish antibiotic-fre non-vir gene deliveri sustain transgen express may
ucla publish non-vir edit strategi matur primari innat lymphocyt cell may
asklepio biopharmaceut privat appoint tim trost chief offic may
avid bioscienc privat appoint michael maclean chief offic may
interna privat partner privat sm phase trial microrna mimic tumor may
radboud univ publish phase i/iia trial data genet attenu malaria vaccin may
unrat announc ind clearanc crispr-edit ipsc-deriv cell therapi may
unrat announc public preclin data dna vaccin may
poseida tx privat initi phase trial autolog car-t therapi metastat may
privat collabor fprf develop gt trigemin neuralgia may
egenesi privat acquir privat icbiotec strengthen product xenotranspl program may
ucla publish dna nanoclew-medi deliveri edit mice may
ucla publish articl scienc advanc demonstr deliveri rna ribonucleoprotein
rnp via nonvir dna nanoclew-bas carrier order edit mous liver technolog abl
effici disrupt gene vivo therebi reduc cholesterol
edita medicin buy employ ex vivo program see may day
summari discuss may viral news genet medicin expect advanc
technolog ultim allow gene edit appli metabol diseas includ cardiovascular diseas
harvard publish scienc dna vaccin candid protect macaqu may
beth israel deaco medic center harvard medic school publish scienc studi test seri in-
hous develop dna vaccin rhesu macaqu
vaccin express differ form spike protein abl induc neutral
antibodi titer compar found convalesc human macaqu author found anim
vaccin vaccin encod full-length spike protein protect challeng viru
 reduct median viral load bronchoalveolar lavag nasal mucosa respect
compar sham control moreov vaccine-induc neutral antibodi titer correl protect
efficaci suggest immun correl protect
page
note vaccin candid develop author harvard studi fund part
author also simultan publish separ articl scienc demonstr infect protect
rhesu macaqu re-exposur viru note neutral antibodi titer vaccin macaqu
dna vaccin studi compar magnitud neutral antibodi titer convalesc
macaqu re-exposur studi median titer full-length spike protein vaccin cohort median titer
convalesc macaqu approxim moreov author includ median titer cohort
convalesc human recov infect
compar vaccin convalesc titer parallel human data observ buy-rat
discuss march research therebi support idea comparison titer convalesc patient
reason metric vaccin activ
agtc buy announc public preclin data provid evid xlrp program may
appli genet technolog announc publish human gene therapi preclin canin data support
select aav vector start dose use on-going phase i/ii trial patient x-link
retin pigmentosa xlrp caus rpgr mutat dose range-find studi author util agtc
proprietari vector deliv via subretin inject differ human transgen candid
rpgr dna sequenc truncat full-length version dog naturally-occur rpgr mutat
transgen demonstr similar level efficaci assess fundu reflect outer nuclear layer
thick correct opsin misloc length cone inner segment dose test howev
full-length candid stronger rpgr express truncat candid dose
case show superior efficaci author select full-length candid
advanc phase i/ii trial discuss may research compani interim phase
i/ii data us appear good better earlier phase i/ii data nightstar acquir
unrat agtc remain track data readout pivot trial start thereaft
pasg buy receiv pediatr diseas design gangliosidosi may
passag announc grant fda rare pediatr diseas design gt
gangliosidosi also fda orphan drug design odd
discuss may leadership call passag remain track file ind
dose first patient top-lin data cohort cohort
unrat purchas share arct buy own may
astrazeneca unrat receiv bn invest barda support vaccin may
astrazeneca announc receiv support bn per us depart
 human servic us biomed advanc research develop author barda support
develop product partner vaccin develop program includ particip
phase trial recal astrazeneca partner univers oxford institut support global develop
distribut chimpanze adenovir vector vaccin
astrazeneca conclud first agreement least million dose total capac sourc one
billion dose compani also note discuss coalit epidem
prepared innov cepi gavi vaccin allianc world organ among
other fair global alloc distribut vaccin around world
oxford also announc immun phase trial complet follow-up on-going addit
oxford begun recruit phase ii/iii trial enrol particip
unrat announc ema applic valid bcma car-t ide-cel multipl myeloma may
compani mention report
page
page
select catalyst genet medicin coverag
report addit data phase i/ii trial hemoglobinopathi
nedosiran report multi-dos data phyox open-label trial primari hyperoxaluria
xlrp end-of-phas ii meet fda xlrp
dose patient clear cell renal cell carcinoma
initi phase ii trial healthi adult vaccin
report addit process data fanconi anemia
submit ind diabet retinopathi
aro-enac file cta cystic fibrosi
present initi clinic data cardiovascular diseas
b-vec initi pivot phase trial deb
initi phase ib studi liver kidney transplant recipi cscc
select lead product candid
suprachoroid initi phase ii trial wet use microinjector
suprachoroid submit ind phase ii trial dr use microinjector
report data secondari endpoint expand cohort phase i/ii hofh
zolgensma anticip approv japan sma
initi investigator-initi phase ii studi recurr glioblastoma
givosiran report addit result envison trial acut hepat porphyria
report phase data hypertriglyceridemia
report phase data dyslipidemia
aro-aat report biopsi data phase ii open label studi antitrypsin defici
report updat data phase i/ii trial pku announc expans cohort dose
updat guidanc time phase i/ii trial initi
submit ind attr
report result phase ii nivolumab combin studi skin cancer cohort
provid interim data cohort phase i/ii trial mp ii
provid program updat preclin develop diseas
provid data cohort phase i/iia trial wet
figur dicerna expect import data read-out
page
select catalyst genet medicin coverag
report phase ii interim analysi healthi adult cmv vaccin
report top-line result realiti observ natur histori studi lhon
submit ema lhon
report initi phase data danon diseas
report preliminari process data fanconi anemia
report updat data phase i/ii trial lad-i
report preliminari phase data pyruv kinas defici
report top-line result cohort phase i/ii pioneer trial retin pigmentosa
report multipl dose data chronic hepat infect
begin enrol patient plan phase i/ii clinic trial diabet retinopathi
present data cohort includ optic phase studi wet
report interim data adult dose group phase i/ii trial
xlrp report interim analysi group mo data group pi/ii trial xlrp
dose patient phase i/ii trial antitrypsin defici
report initi data phase i/ii studi batten diseas
b-vec initi clinic studi eu deb
initi dose patient clinic studi attr
submit ind diseas
initi pivot trial subretin deliveri wet
suprachoroid initi phase ii trial dr use microinjector
updat enrol cohort phase i/ii pioneer trial retin pigmentosa
program file ind oncology/inflammatori indic
vy-aadc present result trial result trial pd
lumasiran potenti fda/ema approv primari hyperoxaluria type
etranadez report top-line data pt pivot phase hope-b studi hem
zolgensma anticip approv switzerland canada australia sma
xlrp initi pivot phase trial xlrp
present initi proof concept data clear cell renal cell carcinoma
present stage data gangliosidosi
report initi data phase i/ii trial b-cell malign
complet adult low-dos cohort treat adult mid-dos cohort
file ind sickl cell diseas
report result phase studi less ici respons tumor
report result phase ii nivolumab combin studi multipl solid tumor
report result monotherapi studi liver kidney transplant recipi cscc
report data nci trial combin checkpoint inhibitor gi cancer
initi piii studi hypertriglyceridemia
initi piii studi dyslipidemia
submit ind file hemophilia
figur regenxbio replimun uniqur expect import data read-out
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur week end may genet medicin vivo gt ex vivo gt ge srna mrna
page
week-over-week perform chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm prevail n-f genet gene therapiesaav gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm bluebird editingtechnologytickerratingccm ptupsideclosechang changemc mm allogen therapytechnologytickerratingccm ptupsideclosechang changemc mm arcturu pharmaceut
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur may vs feb genet medicin vivo gt ex vivo gt ge srna mrna
page
chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm adverum n-f genet gene therapiesaav gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm bluebird editingtechnologytickerratingccm ptupsideclosechang changemc mm allogen therapytechnologytickerratingccm ptupsideclosechang changemc mm arcturu pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public genet medicin vivo gt ex vivo gt gene edit srna mrna therapi companiesend-monthli market cap select compani januari present
page
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public vivo gene therapi companiesend-monthli market cap select compani januari present
page
figur public ex vivo gene therapi companiesend-monthli market cap select compani januari present
page
figur public gene edit companiesend-monthli market cap select compani januari present
page
corpor report factset chardan atrx bntc rgl sln ln exclud due modest size
figur public srna mrna therapi companiesend-monthli market cap select compani januari present
page
vivo gene therapi comp krystal meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public vivo gene therapi companiesw prefer buy buy buy qure buy greater potenti drive upsid space
page
targettargetccmpriceccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighhighp shareshareof genet technolog gene therapiesaxgtbuyaav medicinesfixxbuyaav n-f pharmaceuticalsrcktbuyaav privat vivogt compani molecular akouo ask cardiac inhibitor estev freelin gener horama stride tamid taysha gene therapi tenaya vivet note marin lysogen ultragenyx addit unrat public compani genethon relev non-profit organ pharmaceut
gene edit comp see greater upsid potenti intellia
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name cll model current market cap
figur gene editingw broadli expect out-performance crispr gene edit sector higher potenti perform buy
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof privat gene edit companiescarib scienc egenesi emendo therapeut excis mammoth scienc myogen poseida recombinet spotlight trucod gene repair verv technolog pharmaceut
srna mrna therapi comp alnylam buy unrat prefer name
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy unrat greater potenti drive upsid entir srna mrna space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
crispr
sickl cell diseas beta-thalassemia
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
page
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
price prv
figur prioriti review voucher prv sold million million
page
date fda rpdd
ultragenyx genetx
retin pigmentosa exon mutat
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
genetx ultragenyx
crispr vertex
crispr vertex
polyneuropathi hattr amyloidosi
frontotempor dementia grn mutat
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
ftd grn mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
